Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Sanofi ( (SNY) ) has shared an update.

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up ...